Zhu
FC
et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 Jul 20;S0140-6736(20)31605–6.
[PubMed: 32702299]